EVO | Evotec SE | [NASD]
Index- P/E- EPS (ttm)-0.54 Insider Own- Shs Outstand353.91M Perf Week1.96%
Market Cap3.88B Forward P/E37.62 EPS next Y0.29 Insider Trans- Shs Float353.91M Perf Month17.44%
Income- PEG- EPS next Q0.10 Inst Own0.74% Short Float / Ratio0.01% / 0.92 Perf Quarter14.84%
Sales751.45M P/S5.16 EPS this Y90.40% Inst Trans- Short Interest0.03M Perf Half Y27.30%
Book/sh3.36 P/B3.25 EPS next Y680.00% ROA- Target Price17.00 Perf Year-17.60%
Cash/sh- P/C- EPS next 5Y-4.00% ROE- 52W Range7.80 - 15.04 Perf YTD34.86%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-27.46% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low39.87% ATR0.34
Employees4952 Current Ratio- Sales Q/Q28.70% Oper. Margin- RSI (14)60.69 Volatility1.61% 2.54%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.20 Prev Close10.85
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume34.07K Price10.91
Recom1.80 SMA207.95% SMA508.11% SMA20012.55% Volume6,691 Change0.55%
Date Action Analyst Rating Change Price Target Change
Apr-04-23Upgrade Morgan Stanley Underweight → Equal-Weight $11 → $12
Dec-09-22Initiated H.C. Wainwright Buy $12
Nov-16-22Downgrade Deutsche Bank Buy → Hold
Aug-10-22Downgrade Morgan Stanley Overweight → Underweight $23 → $16
Mar-02-22Resumed Cowen Outperform
Jan-07-22Resumed Citigroup Neutral
May-12-23 06:30PM
May-09-23 02:55PM
Apr-24-23 04:05PM
Apr-10-23 08:15AM
09:20AM Loading…
Apr-07-23 09:20AM
Mar-28-23 05:20AM
Mar-24-23 03:00AM
Mar-21-23 07:10AM
Mar-16-23 03:05AM
Feb-10-23 02:00AM
Feb-09-23 02:00AM
Feb-07-23 02:00AM
Jan-26-23 02:00AM
07:00AM Loading…
Jan-10-23 07:00AM
Dec-16-22 03:40AM
Nov-12-22 01:32AM
Nov-10-22 11:51PM
Nov-09-22 08:00AM
Nov-08-22 11:02PM
Nov-03-22 07:15AM
Nov-02-22 03:00AM
Oct-28-22 03:20AM
Oct-25-22 01:50AM
Oct-18-22 09:03AM
07:15AM Loading…
Oct-17-22 07:15AM
Sep-21-22 10:06AM
Sep-20-22 01:50AM
Sep-16-22 09:25AM
Sep-01-22 07:33AM
Aug-25-22 01:50AM
Aug-11-22 01:40AM
Aug-10-22 07:54AM
Aug-04-22 05:30AM
Jul-06-22 01:50AM
Jul-05-22 01:50AM
Jun-22-22 10:45AM
Jun-15-22 10:47AM
Jun-14-22 10:23AM
May-30-22 02:00AM
May-19-22 01:50AM
May-17-22 11:33AM
May-10-22 10:55AM
May-04-22 08:45AM
Apr-25-22 04:03PM
Apr-22-22 09:23AM
Apr-12-22 01:45AM
Apr-08-22 01:55AM
Apr-05-22 08:55AM
Apr-04-22 11:44AM
Mar-21-22 03:00AM
Mar-02-22 01:50AM
Mar-01-22 01:50AM
Feb-04-22 02:44PM
Jan-25-22 01:55AM
Jan-18-22 03:53AM
Jan-11-22 02:00AM
Jan-03-22 01:55AM
Dec-24-21 11:38AM
Dec-16-21 02:00AM
Dec-15-21 10:38AM
Nov-18-21 07:00AM
Nov-11-21 01:30AM
Nov-10-21 02:00AM
Nov-09-21 09:55AM
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer; Lilly; Almirall; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Janseen Biotech; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.